Actively Recruiting
Ga-68 FAPI PET Before Immunotherapy
Led by Ankara University · Updated on 2024-06-11
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
Sponsors
A
Ankara University
Lead Sponsor
L
Liv Hospital Ankara
Collaborating Sponsor
AI-Summary
What this Trial Is About
It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.
CONDITIONS
Official Title
Ga-68 FAPI PET Before Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histopathologically confirmed diagnosis of pleural mesothelioma
- Scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
- Provided informed consent to participate in the study
You will not qualify if you...
- Eastern Cooperative Oncology Group (ECOG) performance status greater than 2
- Did not provide informed consent to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ankara University School of Medicine
Ankara, Turkey (Türkiye), 06590
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here